Merck ditches vibostolimab and favezelimab following huge pivotal programmes.

Relativity-104 is revealed as a failure, and the phase 3 it just spawned could fail too.

After several disappointments Bristol at last turns its Lag3/PD-1 combo to first-line lung cancer.

After Tacti-003’s controlled cohorts fail, Immutep plays up single-arm data in PD-L1 non-expressers.

Predictably Tacti-003 fails, but funding is secured – from investors, not a partner.

April will see the first big scientific meeting of the year, and could herald important data from Immutep and GSK.

Results with eftilagimod alpha in first-line head and neck cancer threaten to cloud partnering prospects.

A just revealed phase 3 trial will apparently pit a fixed-dose combo head to head against Opdualag.